David G. Bostwick a, ⁎, 1
Report of Consensus Group 1: Pathobiology of Prostate Cancer: Implications for Focal Therapy
, 5
Dr. Bostwick is a study investigator for Bioniche, Dendreon, DiagnoCure, Endocare, Genotherapeutics, GlaxoSmithKline, and Health Tronics; and is the founder and majority shareholder in Bostwick Laboratories.
, David J. Waters 1
Report of Consensus Group 1: Pathobiology of Prostate Cancer: Implications for Focal Therapy
, Edward R. Farley 1
Report of Consensus Group 1: Pathobiology of Prostate Cancer: Implications for Focal Therapy
, Isabelle Meiers 1
Report of Consensus Group 1: Pathobiology of Prostate Cancer: Implications for Focal Therapy
, Daniel Rukstalis 2
Report of Consensus Group 2: Definition and Rationale of Focal Therapy for Prostate Cancer
, William A. Cavanaugh 2
Report of Consensus Group 2: Definition and Rationale of Focal Therapy for Prostate Cancer
, Haakon Ragde 2
Report of Consensus Group 2: Definition and Rationale of Focal Therapy for Prostate Cancer
, Martin K. Dineen 2
Report of Consensus Group 2: Definition and Rationale of Focal Therapy for Prostate Cancer
, Duke Bahn 3
Report of Consensus Group 3: Patient Selection Factors for Focal Therapy for Prostate Cancer
, Stephen Scionti 3
Report of Consensus Group 3: Patient Selection Factors for Focal Therapy for Prostate Cancer
, Richard Babian 3
Report of Consensus Group 3: Patient Selection Factors for Focal Therapy for Prostate Cancer
, David S. Ellis 3
Report of Consensus Group 3: Patient Selection Factors for Focal Therapy for Prostate Cancer
, John C. Rewcastle 3
Report of Consensus Group 3: Patient Selection Factors for Focal Therapy for Prostate Cancer
, Harry B. Burke 4
Report of Consensus Group 4: 3-Dimensional Prostate Mapping Biopsies for Patients Being Considered for Focal Therapy
, Gerald L. Andriole 4
Report of Consensus Group 4: 3-Dimensional Prostate Mapping Biopsies for Patients Being Considered for Focal Therapy
, Gary Onik b, 4
Report of Consensus Group 4: 3-Dimensional Prostate Mapping Biopsies for Patients Being Considered for Focal Therapy
, 6
Dr. Onik holds stock in Endocare, Inc.
, Al E. Barqawi 4
Report of Consensus Group 4: 3-Dimensional Prostate Mapping Biopsies for Patients Being Considered for Focal Therapy
, John Maksem 4
Report of Consensus Group 4: 3-Dimensional Prostate Mapping Biopsies for Patients Being Considered for Focal Therapy
, Winston E. Barzell 4
Report of Consensus Group 4: 3-Dimensional Prostate Mapping Biopsies for Patients Being Considered for Focal Therapy
a Bostwick Laboratories, Richmond, Virginia, USA
b Department of Radiology and Urology, Division of Surgical Imaging, Center for Surgical Advancement, Celebration Health/Florida Hospital, Celebration, Florida, USA